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Abstract: Glioblastoma (GBM) is the most aggressive and malignant form of primary brain cancer,
characterized by an overall survival time ranging from 12 to 18 months. Despite the progress in
the clinical treatment and the growing number of experimental data aimed at investigating the
molecular bases of GBM development, the disease remains characterized by a poor prognosis. Recent
studies have proposed the existence of a population of GBM cancer stem cells (CSCs) endowed
with self-renewal capability and a high tumorigenic potential that are believed to be responsible
for the resistance against common chemotherapy and radiotherapy treatments. Reelin is a large
secreted extracellular matrix glycoprotein, which contributes to positioning, migration, and laminar
organization of several central nervous system structures during brain development. Mutations of
the reelin gene have been linked to disorganization of brain structures during development and
behavioral anomalies. In this study, we explored the expression of reelin in GBM and its related
peritumoral tissue and performed the same analysis in CSCs isolated from both GBM (GCSCs)
and peritumoral tissue (PCSCs) of human patients. Our findings reveal (i) the higher expression
of reelin in GBM compared to the peritumoral tissue by immunohistochemical analysis, (ii) the
mRNA expression of both reelin and its adaptor molecule Dab1 in either CSC subtypes, although
at a different extent; and (iii) the contribution of CSCs-derived reelin in the migration of human
primary GBM cell line U87MG. Taken together, our data indicate that the expression of reelin in GBM
may represent a potential contribution to the regulation of GBM cancer stem cells behavior, further
stimulating the interest on the reelin pathway as a potential target for GBM treatment.
Keywords: cancer stem cells; glioblastoma; peritumoral tissue; reelin
1. Introduction
GBM is a malignant and a very aggressive form of primary brain cancer whose clinical
treatment represents a major challenge based on its great heterogeneity and the high
frequency of recurrences. Despite the aggressive treatment of patients with a combination
of surgery followed by radio and chemotherapy, GBM remains essentially an incurable
disease with a median survival time ranging from 12 to 18 months [1–3]. Although most
studies related to GBM are focused on the core tumor area, increasing interest has recently
raised toward the involvement of the peritumoral area of GBM [4–12]. Infiltrating tumor
cells into this apparently healthy parenchyma appears critical for the onset of recurrence,
causing the surgical resection of the tumor to be fruitless. Therefore, there is an urgent
need to identify novel markers both in GBM and in the peritumoral tissue that may be
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beneficial to counteract the progression of the disease. Reelin is a large secreted extracellular
glycoprotein of approximately 400 kDa [13,14] that plays a key role in the regulation of
neuronal migration during mammalian brain development [15]. Studies performed in the
null reeler mouse have suggested that the serine protease activity of reelin is crucial for its
function in the developing brain [16]. See [17,18] for a detailed review of the main structural
and functional features of the reelin glycoprotein in the nervous system development.
Signaling mechanisms triggered by reelin depend on the recruitment of distinct cell surface
receptors, i.e., very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor
2 (ApoER2 or LRP8) [19–22], α3β1 integrin [23–25], and members of the cadherin-related
neuronal receptor (CNR) family [26]. ApoER2 and VLDLR show the highest affinity
for reelin [27] and mediate their intracellular signaling following src-mediated tyrosine
phosphorylation of the intracellular adapter protein disabled-1 (Dab1) [19,28–32], which
in turn activates a number of downstream adaptor proteins, including Crk, C3G, Rap1,
and phosphatidylinositol-3-kinase (PI3K) [25,31,33–36]. Interestingly, a number of studies
has reported changes in the expression of reelin in different cancer types even outside
the nervous system [37]. Reelin expression has been found reduced in breast [38–40],
colorectal [41,42], and pancreatic cancers [43], while it has been found to be increased in
retinoblastoma [44], myelomas [45], and prostate cancers [39,46,47]. Here, we investigated
the expression of reelin in human tissue samples obtained from tumoral lesion and the
peritumoral area of GBM. We also investigated the expression of both reelin and its adapter
molecule Dab1 in CSCs isolated from GBM (GCSCs) and from the peritumoral tissues
(PCSCs) derived from GBM patients as previously reported [46] and further characterized
by our group [4–7,9–11]. Finally, to explore the potential biological role of reelin in GBM,
we studied its effect on the migration of human glioma cell line U87MG. Although the
precise molecular mechanisms are still unclear, our data suggest an interesting role of
secreted reelin in stimulating the migratory capability of GBM CSCs, therefore opening a
new avenue in the investigation of the potential biological role of reelin in GBM.
2. Materials and Methods
2.1. GBM Tissue and Cell Cultures
Isolation and characterization of neurospheres derived from both samples of GBM
(glioblastoma cancer stem cells, GCSCs) and peritumoral tissue (peritumoral tissue cancer
stem cells, PCSCs) were performed by Prof. A. Vescovi and his group [46,47]. The detailed
methodology was also reported in our previous papers [9–11]. GCSCs and PCSCs were
cultured in a NeuroCult™ NS-A Proliferation Kit (Stemcell Technologies Inc, Vancouver,
BC, Canada) supplemented with 20 ng/mL human recombinant EGF, 10 ng/mL human re-
combinant bFGF, and 2 ug/mL heparin (all from StemCell Technologies Inc.). The U87MG
grade IV glioma cell line was maintained in DMEM containing 10% (v/v) fetal calf serum,
200 mM L-glutamine, and 100 units/mL penicillin/streptomycin (Life Technologies Carls-
bad, CA, USA). All cell types were maintained at 37 ◦C in a 5% CO2 humidified atmosphere.
Recombinant reelin was purchased from R&D Systems (Minneapolis, MN, USA).
2.2. Immunohistochemistry and Stereological Analysis of GBM and Peritumoral Tissue
Paraffin-embedded tissue sections from tumor and peritumoral samples of four pa-
tients were used for immunohistochemical analysis. In brief, after blocking endogen perox-
idase, histological sections were incubated with either monoclonal anti-reelin MAB5364
(Millipore) or with appropriate IgG1 control antibody overnight at 4 ◦C. Specimens were
then incubated with an HRP/Fab polymer conjugate (SuperPicTure Polymer Detection
Kit, Invitrogen, Camarillo, CA, USA). Immunopositive cells were visualized by brown
DAB (Vector Laboratories, Inc., Burlingame, CA, USA) staining and sections were lightly
counterstained with Mayer’s hematoxylin. For accurate quantification of immunopositive
cells, we employed an unbiased stereological technique by means of the Stereo Investigator
System (Stereo Investigator software, Version 9.14© 2010, MicroBrightField Europe, Magde-
burg, Germany) as previously described [9,48,49]. This technique allows quantitative and
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unbiased evidence of a three-dimensional structure to be obtained, based on the analysis
performed on two-dimensional histological sections [50]. The cellular density of reelin-
negative (−) and reelin-positive (+) cells was determined by dividing the number of cells
from three different fields by the area of region of interest (ROI) of GBM and peritumoral
tissue with the Stereo Investigator software (Version 9.14© 2010, MicroBrightField Europe,
Magdeburg, Germany).
2.3. Quantitative RT-PCR of Reelin Expression in GCSCs and PCSCs
For real-time PCR analysis of reelin expression, total RNA was extracted from GC-
SCs and PCSCs with the TRIZOL Reagent (Life Technologies Corporation, Gaithersburg,
MD, USA) according to the manufacturer’s instructions. Total RNA was therefore retro-
transcribed into single-stranded cDNA by a standard 20-µL RT reaction with the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA USA).
cDNA generated from the reverse transcription reactions was amplified by real-time PCR
with the SensiMix SYBR kit (Bioline, London, UK) in a total volume of 20 µL with the Step
One Real-Time PCR System (Life Technologies Corporation). The following primers cou-
ples were used for PCR reactions: reelin, 5′-AAATGAGCATGGGCTGTAGCAAGC-3′ and
5′-ACTCTTCGGTGACAAGATGCCAGT-3; Dab1, 5′-TGAAACTCAAGGGCGTTGTTGCT
G-3′ and 5′-TCCAAAGGCCCGGTGATCTGTAAT-3′; β-Actin, 5′TGCACCACACCTTC
TACAATGA-3′ and 5′CAGCCTGGATAGCAACGTACAT-3′. The level of gene expression
was expressed as the relative fold change vs. the β-actin messenger RNA using the ∆∆Ct
method [51] using the Step One System Software (Life Technologies Corporation).
2.4. Evaluation of U87MG Cell Migration
The evaluation of cell migration was performed using the modified Boyden chamber
assay with 8.0 µm polycarbonate membrane inserts (BD Biosciences, Bedford, MA, USA).
A suspension of 200,000 U87MG cells was added to the upper well of the Boyden chamber
and 500 µL of GCSCs- or PCSCs-derived conditioned medium were added to the lower
well either in the presence or absence of 200 ng/mL of recombinant reelin. Cells were
incubated under the described conditions for 18 h in a 37 ◦C, 5% CO2 incubator. At the end
of the incubation, membranes were rinsed in PBS, fixed by 3.7% formaldehyde for 10 min at
room temperature, and permeabilized by 100% methanol for 20 min at room temperature.
After scraping off non-migrated cells, polycarbonate membranes were stained with DAPI
and migrated cells were counted under a fluorescence microscope (Nikon Eclipse TS100,
Nikon, Tokyo, Japan). The number of cells, counted from five different microscopic fields
for each sample, was then averaged and graphed.
2.5. Statistical Analysis
Statistical analysis was performed by one-way ANOVA, using the Sigma Stat soft-
ware package (version 3.1 for Windows). Differences between groups were tested by the
Bonferroni-corrected t-test.
3. Results
3.1. Expression of Reelin in GBM
To investigate the expression of reelin, we first performed immunohistochemistry
analysis on both GBM and peritumoral tissue specimens. This analysis clearly revealed the
presence of a high number of reelin-positive cells in GBM compared to the peritumoral
tissue (Figure 1A,B). Moreover, reelin was also found to be expressed at the level of
endothelium in both GBM and peritumoral tissue, in agreement with previous findings
of reelin expression in brain endothelial cells [48]. Due to the structural complexity of
samples studied and to ensure rigorous and unbiased quantitative estimation of data
generated by immunohistochemistry, we turned to the stereological analysis [9]. This
analysis demonstrated that the cell density (cells/mm2) of reelin (+) cells was significantly
(p = 0.015) higher in GBM than in peritumoral tissue (Figure 1C). Our data are consistent
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with the expression of reelin in both GBM and the corresponding peritumoral area, and
with a higher cell density revealed in GBM. These data are in apparent contrast with
data published by others that reported a diminished expression of reelin in GBM samples
compared to non-pathological samples. We believe that this discrepancy may be due to the
extreme heterogeneity of samples employed in the above-mentioned work [49]. Indeed,
while our analysis was performed only on grade IV GBM samples, the previous study
included primary and secondary glioblastomas and different types of astrocytoma.
Figure 1. Expression of reelin and stereological analysis of GBM and peritumor tissue. (A,B), Im-
munohistochemical analysis of reelin expression in GBM (A) and peritumor tissue (B), representative
of 4 patients. In GBM, reelin immunopositivity was detected in the cytoplasm of tumor cells and
in endothelial cells. (B), reelin immunolocalization in the endothelium, and in the cytoplasm of
apparently normal cells of peritumor tissue. (C) Stereological analysis of cell density in both GBM
and peritumor tissue from 4 different patients. Cell density was determined by dividing cell counts
by the area of the ROI, (* p = 0.02; ** p = 0.015). Bars show the mean of cell counts ± standard
deviation of 4 GBM pairs.
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3.2. Expression of Reelin and DAB1 mRNA in GCSCs and PCSCs
We next investigated, by real time-PCR (qPCR) analysis, the expression of both reelin
and its adaptor molecule Dab1 mRNA in both GCSCs and PCSCs isolated from four
different GBM patients. Our results demonstrated a marked expression of both reelin and
Dab1 transcripts in both GCSCs and PCSCs. However, while reelin mRNA expression was
clearly higher in PCSCs compared to GCSCs in all the samples analyzed, the expression of
Dab1 mRNA appeared more heterogeneous, and was upregulated in three out of four PCSC
samples (Figure 2). This data indicated that both GCSCs and PCSCs are endowed with the
ability of expressing reelin, although at a different extent. Moreover, the expression of Dab1
mRNA suggests the possible activity of the reelin pathway in PCSCs rather than GCSCs.
Figure 2. Expression of reelin and Dab1 mRNA by qRT-PCR in GCSCs and PCSCs of four patients. The level of mRNAs
of reelin and Dab1 were evaluated by qRT-PCR as described in the Section 2. Upper panels show that mRNA of reelin
was higher in all PCSCs compared to GCSCs. Lower panels show that mRNA expression of Dab1 was found higher in
three out four examined samples of PCSCs. Bars show the mean of mRNA expression data ± standard deviation from
three experiments.
3.3. Effects of Reelin and CSCs Culture Medium in the Migration of Human Malignant Glioma
Cell Line U87MG
To deepen the significance of reelin expression in CSCs, we then investigated the
potential effect of reelin released by GCSCs and PCSCs. Therefore, we used both GCSC-
and PCSC-derived conditioned media (CM) to treat a target tumor cell type, i.e., U87MG in
a Boyden chamber assay. The results of these experiments showed that PCSC- and PCSC-
derived CM were able to induce migration of U87MG only in the presence of 200 ng/mL
recombinant reelin (Figure 3A–F). These data indicated a possible disorganized secretory
mechanism in CSCs that prevented the release of soluble reelin into the culture medium.
Notably, in the presence of recombinant reelin, we also observed the formation of small
spheroid-like structures (Figure 3B,D,F), similar to what was already reported in neurons
and glial cells [52], indicating that U87MG cells were responsive to reelin stimulation. Data
obtained from different assays were collected, analyzed, and graphed (Figure 3G).
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Figure 3. Effects of reelin and CSCs culture medium on U87MG migration. Cells were allowed
to migrate for 18 h across the membrane in the Boyden chamber assay in the presence or absence
of recombinant reelin. * p < 0.001 ** p < 0.05. (A–F), representative immunofluorescence images
of migrated and DAPI-stained U87MG. (G), shows the average of migrated cells incubated with
conditioned medium with or without 200 ng/mL recombinant reelin. Results are expressed as the
number of cells/field; * p < 0.001 ** p < 0.05. Bars show the mean of migrated cells ± standard
deviation from three experiments.
4. Discussion
The glycoprotein reelin has been demonstrated to be critical during the positioning of
migrating post-mitotic neurons and the laminar organization of several central nervous
system (CNS) structures during development [13]. Moreover, it has been found transiently
expressed both in the peripheral nervous system (PNS) [53] and other tissues [54–56].
The idea that reelin may function outside of the CNS and PNS has been supported by
recent works that have linked the reelin signaling pathway to different cancers, such as
prostate, gastric, and breast cancers. However, clear evidence of the involvement of reelin
in tumor development has not been fully elucidated. Here, we provide evidence that
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reelin is expressed in both GBM and its adjacent peritumoral tissue at a different extent.
Interestingly, our immunohistochemical analyses on GBM samples and peritumoral tissue
indicate the presence of reelin in both areas of the brain and suggest a possible activity of the
reelin pathway in GBM progression. The higher expression of reelin in GBM may indicate
a possible contribution of the protein in the regulation of cell survival. It has been, indeed,
demonstrated that reelin functions as an anti-apoptotic factor, promoting cell survival
through the Dab1-activated Akt pathway. In addition, PI3-kinase inhibitors counteract
reelin-induced cell survival [57]. Notably, although CSCs have been detected in many types
of gliomas, few studies have investigated their significance in GBM adjacent peritumoral
tissue [9–11]. Our data on the expression of the major adaptor molecule of reelin, i.e., Dab1,
highlight the involvement of reelin pathway in the GCSCs and PCSCs of GBM. However,
the precise mechanism remains elusive. In this respect, we report here the expression of
both reelin and Dab1 mRNAs in GCSCs and PCSCs. Specifically, reelin transcript was found
to be expressed higher in PCSCs compared to GCSCs, whereas the expression of Dab1
mRNA appeared more heterogeneous within pairs, being overexpressed in three out of
four PCSCs samples. These findings are in accordance with the high heterogeneity of CSCs
couples derived from GBM patients, as previous reported [9,10]. In addition, the higher
expression of both reelin and Dab-1 transcripts in PCSCs compared to GCSCs may suggest a
crucial function of reelin as a potential prognostic marker for a new therapy of GBM. On the
other hand, the expression of a detectable level of reelin in tissues along with the expression
of both reelin and Dab1 mRNA in GCSCs, particularly in PCSCs, prompted us to investigate
the biological significance of reelin signaling in GBM. Our in vitro experiments show that
administration of 200 ng/mL recombinant reelin to U87MG for 18 h in culture, triggered
cell migration and stimulated the formation of detectable spheroids, supporting previous
findings [57]. Interestingly, when cultivated with conditioned medium collected from both
GCSCs and PCSCs in culture without recombinant reelin, we did not observe marked
U87MG cell migration. These results raise questions regarding the possible anomaly
of the secretory mechanism of reelin or the occurrence of an aberrant post-translational
modification of the protein that prevents it from being correctly released from CSCs. Taken
together, our results indicate that: (a) the expression of reelin protein is remarkably higher
in GBM tissue and PCSCs; (b) the expression of reelin transcript is higher in PCSCs rather
than GCSCs, while the Dab1 mRNA level is more heterogeneous, being highly expressed
in three out of four PCSCs samples; and (c) administration of reelin to U87MG induces
migration as well as spheroid-like structure formation in vitro. Further investigation is
necessary to understand the contribution of reelin-induced signaling in the maintenance
of PCSC and GCSC stem cell behavior. Therefore, we hypothesize a possible function
of reelin in the regulation of the invasiveness of CSCs, specifically from the peritumoral
tissue, which can be prospective for the development of new therapeutic approaches for
the treatment of GBM patients.
5. Conclusions
The extracellular matrix glycoprotein reelin plays a crucial role during mammalian
brain development by contributing to the regulation of neuronal migration, establishment
and branching of dendrites, synaptogenesis and synaptic plasticity. Reelin has been as
well associated to some human brain disorders in the adulthood, such as lissencephaly,
autism, mental disorders and Alzheimer’s disease. However, the involvement of reelin
signaling in brain tumors has been poorly investigated. In this study we observed a
higher expression of reelin and Dab1 transcripts in both peritumoral area and peritumoral-
derived CSCs, with respect to the tumor core. Taken together, our findings might suggest a
potential involvement of the reelin signaling in GBM pathology and possibly in the onset
of tumor recurrence that frequently originate from the peritumoral region. Therefore, we
believe that deepening the role of reelin signaling in GBM may be crucial to develop novel
treatment opportunities.
Brain Sci. 2021, 11, 745 8 of 10
Author Contributions: Conceptualization and methodology; A.D., G.S., F.B., A.F.; investigation and
formal analysis; F.B.; writing and original draft preparation; A.D., G.S., F.B., A.F. All authors have
read and agreed to the published version of the manuscript.
Funding: This work was supported by the Italian Ministry for Education University and Research
(MIUR, 2010) FIRB Project RBAP10KJC5 to GS; the Catholic University of the Sacred Heart within the
framework of its programs for the promotion and dissemination of scientific research, Linea D.1 2019
to A.D., and by Ateneo Sapienza University (Ref. Number RP11816427B97420) to A.F.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Walker, M.D.; Alexander, E.; Hunt, W.E.; Maccarty, C.S.; Mahaley, M.S.; Mealey, J.; Norrell, H.A.; Owens, G.; Ransohoff, J.; Wilson,
C.B.; et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J. Neurosurg. 1978, 49, 333–343.
[CrossRef] [PubMed]
2. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn,
U.; et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005, 352, 987–996.
[CrossRef] [PubMed]
3. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.;
Belanger, K.; et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival
in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10, 459–466.
[CrossRef]
4. Lama, G.; Mangiola, A.; Anile, C.; Sabatino, G.; De Bonis, P.; Lauriola, L.; Giannitelli, C.; La Torre, G.; Jhanwar-Uniyal, M.; Sica,
G.; et al. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. Int. J. Oncol. 2007, 30, 1333–1342.
[CrossRef]
5. Mangiola, A.; Lama, G.; Giannitelli, C.; De Bonis, P.; Anile, C.; Lauriola, L.; La Torre, G.; Sabatino, G.; Maira, G.; Jhanwar-Uniyal,
M.; et al. Stem Cell Marker Nestin and c-Jun NH2-Terminal Kinases in Tumor and Peritumor Areas of Glioblastoma Multiforme:
Possible Prognostic Implications. Clin. Cancer Res. 2007, 13, 6970–6977. [CrossRef]
6. Sica, G.; Lama, G.; Anile, C.; Geloso, M.C.; La Torre, G.; De Bonis, P.; Maira, G.; Lauriola, L.; Jhanwar-Uniyal, M.; Mangiola, A.;
et al. Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma. Int. J. Oncol. 2010, 38,
41–49. [CrossRef]
7. Mangiola, A.; Saulnier, N.; De Bonis, P.; Orteschi, D.; Sica, G.; Lama, G.; Pettorini, B.L.; Sabatino, G.; Zollino, M.; Lauriola, L.; et al.
Gene Expression Profile of Glioblastoma Peritumoral Tissue: An Ex Vivo Study. PLoS ONE 2013, 8, e57145. [CrossRef]
8. Cenciarelli, C.; Marei, H.E.S.; Zonfrillo, M.; Pierimarchi, P.; Paldino, E.; Casalbore, P.; Felsani, A.; Vescovi, A.L.; Maira, G.;
Mangiola, A. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and
anti-EGFR treatment. Mol. Cancer 2014, 13, 247. [CrossRef]
9. D’Alessio, A.; Proietti, G.; Lama, G.; Biamonte, F.; Lauriola, L.; Moscato, U.; Vescovi, A.; Mangiola, A.; Angelucci, C.; Sica, G.
Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells. Oncotarget 2016,
7, 78541–78556. [CrossRef]
10. Lama, G.; Mangiola, A.; Proietti, G.; Colabianchi, A.; Angelucci, C.; Alessio, A.D.; De Bonis, P.; Geloso, M.C.; Lauriola, L.; Binda,
E.; et al. Progenitor/Stem Cell Markers in Brain Adjacent to Glioblastoma: GD3 Ganglioside and NG2 Proteoglycan Expression. J.
Neuropathol. Exp. Neurol. 2016, 75, 134–147. [CrossRef]
11. Angelucci, C.; D’Alessio, A.; Lama, G.; Binda, E.; Mangiola, A.; Vescovi, A.L.; Proietti, G.; Masuelli, L.; Bei, R.; Fazi, B.; et al.
Cancer stem cells from peritumoral tissue of glioblastoma multiforme: The possible missing link between tumor development
and progression. Oncotarget 2018, 9, 28116–28130. [CrossRef]
12. D’Alessio, A.; Proietti, G.; Sica, G.; Scicchitano, B.M. Pathological and Molecular Features of Glioblastoma and Its Peritumoral
Tissue. Cancers 2019, 11, 469. [CrossRef]
13. D’Arcangelo, G.; Miao, G.G.; Chen, S.-C.; Scares, H.D.; Morgan, J.I.; Curran, T. A protein related to extracellular matrix proteins
deleted in the mouse mutant reeler. Nature 1995, 374, 719–723. [CrossRef]
14. Ogawa, M.; Miyata, T.; Nakajima, K.; Yagyu, K.; Seike, M.; Ikenaka, K.; Yamamoto, H.; Mikoshibat, K. The reeler gene-associated
antigen on cajal-retzius neurons is a crucial molecule for laminar organization of cortical neurons. Neuron 1995, 14, 899–912.
[CrossRef]
15. Tissir, F.; Goffinet, A.M. Reelin and brain development. Nat. Rev. Neurosci. 2003, 4, 496–505. [CrossRef]
16. Quattrocchi, C.C.; Wannenes, F.; Persico, A.M.; Ciafre’, S.A.; D’Arcangelo, G.; Farace, M.G.; Keller, F. Reelin Is a Serine Protease of
the Extracellular Matrix. J. Biol. Chem. 2002, 277, 303–309. [CrossRef]
17. Fatemi, S.H. Reelin glycoprotein: Structure, biology and roles in health and disease. Mol. Psychiatry 2004, 10, 251–257. [CrossRef]
18. Armstrong, N.C.; Anderson, R.C.; McDermott, K.W. Reelin: Diverse roles in central nervous system development, health and
disease. Int. J. Biochem. Cell Biol. 2019, 112, 72–75. [CrossRef]
19. D’Arcangelo, G.; Homayouni, R.; Keshvara, L.; Rice, D.S.; Sheldon, M.; Curran, T. Reelin Is a Ligand for Lipoprotein Receptors.
Neuron 1999, 24, 471–479. [CrossRef]
Brain Sci. 2021, 11, 745 9 of 10
20. Hiesberger, T.; Trommsdorff, M.; Howell, B.W.; Goffinet, A.; Mumby, M.C.; Cooper, J.A.; Herz, J. Direct Binding of Reelin to VLDL
Receptor and ApoE Receptor 2 Induces Tyrosine Phosphorylation of Disabled-1 and Modulates Tau Phosphorylation. Neuron
1999, 24, 481–489. [CrossRef]
21. Trommsdorff, M.; Gotthardt, M.; Hiesberger, T.; Shelton, J.; Stockinger, W.; Nimpf, J.; Hammer, R.E.; Richardson, J.A.; Herz, J.
Reeler/Disabled-like Disruption of Neuronal Migration in Knockout Mice Lacking the VLDL Receptor and ApoE Receptor 2. Cell
1999, 97, 689–701. [CrossRef]
22. Dlugosz, P.; Nimpf, J. The Reelin Receptors Apolipoprotein E receptor 2 (ApoER2) and VLDL Receptor. Int. J. Mol. Sci. 2018,
19, 3090. [CrossRef]
23. Dulabon, L.; Olson, E.C.; Taglienti, M.G.; Eisenhuth, S.; McGrath, B.; Walsh, C.A.; Kreidberg, J.A.; Anton, E. Reelin Binds α3β1
Integrin and Inhibits Neuronal Migration. Neuron 2000, 27, 33–44. [CrossRef]
24. Costa, E.; Davis, J.; Grayson, D.R.; Guidotti, A.; Pappas, G.D.; Pesold, C. Dendritic Spine Hypoplasticity and Downregulation of
Reelin and GABAergic Tone in Schizophrenia Vulnerability. Neurobiol. Dis. 2001, 8, 723–742. [CrossRef]
25. Sekine, K.; Kawauchi, T.; Kubo, K.-I.; Honda, T.; Herz, J.; Hattori, M.; Kinashi, T.; Nakajima, K. Reelin Controls Neuronal
Positioning by Promoting Cell-Matrix Adhesion via Inside-Out Activation of Integrin α5β1. Neuron 2012, 76, 353–369. [CrossRef]
26. Senzaki, K.; Ogawa, M.; Yagi, T. Proteins of the CNR Family Are Multiple Receptors for Reelin. Cell 1999, 99, 635–647. [CrossRef]
27. Lee, G.H.; D’Arcangelo, G. New Insights into Reelin-Mediated Signaling Pathways. Front. Cell. Neurosci. 2016, 10, 122. [CrossRef]
28. Howell, B.W.; Herrick, T.M.; Cooper, J.A. Reelin-induced tryosine phosphorylation of Disabled 1 during neuronal positioning.
Genes Dev. 1999, 13, 643–648. [CrossRef]
29. Keshvara, L.; Benhayon, D.; Magdaleno, S.; Curran, T. Identification of Reelin-induced Sites of Tyrosyl Phosphorylation on
Disabled 1. J. Biol. Chem. 2001, 276, 16008–16014. [CrossRef]
30. Arnaud, L.; Ballif, B.A.; Förster, E.; Cooper, J.A. Fyn Tyrosine Kinase Is a Critical Regulator of Disabled-1 during Brain Develop-
ment. Curr. Biol. 2003, 13, 9–17. [CrossRef]
31. Ballif, B.A.; Arnaud, L.; Arthur, W.T.; Guris, D.; Imamoto, A.; Cooper, J.A. Activation of a Dab1/CrkL/C3G/Rap1 Pathway in
Reelin-Stimulated Neurons. Curr. Biol. 2004, 14, 606–610. [CrossRef] [PubMed]
32. Bock, H.H.; May, P. Canonical and Non-canonical Reelin Signaling. Front. Cell. Neurosci. 2016, 10, 166. [CrossRef] [PubMed]
33. Jossin, Y.; Goffinet, A.M. Reelin Signals through Phosphatidylinositol 3-Kinase and Akt to Control Cortical Development and
through mTor To Regulate Dendritic Growth. Mol. Cell. Biol. 2007, 27, 7113–7124. [CrossRef] [PubMed]
34. Park, T.-J.; Curran, T. Crk and Crk-Like Play Essential Overlapping Roles Downstream of Disabled-1 in the Reelin Pathway. J.
Neurosci. 2008, 28, 13551–13562. [CrossRef]
35. Franco, S.J.; Martinez-Garay, I.; Gil-Sanz, C.; Harkins-Perry, S.R.; Müller, U. Reelin Regulates Cadherin Function via Dab1/Rap1
to Control Neuronal Migration and Lamination in the Neocortex. Neuron 2011, 69, 482–497. [CrossRef]
36. Dlugosz, P.; Teufl, M.; Schwab, M.; Kohl, K.; Nimpf, J. Disabled 1 Is Part of a Signaling Pathway Activated by Epidermal Growth
Factor Receptor. Int. J. Mol. Sci. 2021, 22, 1745. [CrossRef]
37. Khialeeva, E.; Carpenter, E.M. Nonneuronal roles for the reelin signaling pathway. Dev. Dyn. 2017, 246, 217–226. [CrossRef]
38. Ma, X.-J.; Dahiya, S.; Richardson, E.; Erlander, M.; Sgroi, D.C. Gene expression profiling of the tumor microenvironment during
breast cancer progression. Breast Cancer Res. 2009, 11, R7. [CrossRef]
39. Stein, T.; Cosimo, E.; Yu, X.; Smith, P.R.; Simon, R.; Cottrell, L.; Pringle, M.-A.; Bell, A.K.; Lattanzio, L.; Sauter, G.; et al. Loss of
Reelin Expression in Breast Cancer Is Epigenetically Controlled and Associated with Poor Prognosis. Am. J. Pathol. 2010, 177,
2323–2333. [CrossRef]
40. Ndoye, A.; Miskin, R.; DiPersio, C. Integrin 31 Represses Reelin Expression in Breast Cancer Cells to Promote Invasion. Cancers
2021, 13, 344. [CrossRef]
41. Vignot, S.; Lefebvre, C.; Frampton, G.M.; Meurice, G.; Yelensky, R.; Palmer, G.; Capron, F.; Lazar, V.; Hannoun, L.; Miller, V.A.;
et al. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: Evaluation of concordance
between genomic and transcriptional profiles. Eur. J. Cancer 2015, 51, 791–799. [CrossRef]
42. Serrano-Morales, J.M.; Vázquez-Carretero, M.D.; Peral, M.J.; Ilundáin, A.A.; Garcia-Miranda, P. Reelin-Dab1 signaling system in
human colorectal cancer. Mol. Carcinog. 2016, 56, 712–721. [CrossRef] [PubMed]
43. Sato, N.; Fukushima, N.; Chang, R.; Matsubayashi, H.; Goggins, M. Differential and Epigenetic Gene Expression Profiling
Identifies Frequent Disruption of the RELN Pathway in Pancreatic Cancers. Gastroenterol. 2006, 130, 548–565. [CrossRef]
44. Seigel, G.M.; Hackam, A.S.; Ganguly, A.; Mandell, L.M.; Gonzalez-Fernandez, F. Human embryonic and neuronal stem cell
markers in retinoblastoma. Mol. Vis. 2007, 13, 823–832.
45. Qin, X.; Lin, L.; Cao, L.; Zhang, X.; Song, X.; Hao, J.; Zhang, Y.; Wei, R.; Huang, X.; Lu, J.; et al. Extracellular matrix protein Reelin
promotes myeloma progression by facilitating tumor cell proliferation and glycolysis. Sci. Rep. 2017, 7, 45305. [CrossRef]
46. Galli, R.; Binda, E.; Orfanelli, U.; Cipelletti, B.; Gritti, A.; De Vitis, S.; Fiocco, R.; Foroni, C.; DiMeco, F.; Vescovi, A. Isolation
and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma. Cancer Res. 2004, 64, 7011–7021.
[CrossRef]
47. Binda, E.; Visioli, A.; Giani, F.; Lamorte, G.; Copetti, M.; Pitter, K.; Huse, J.T.; Cajola, L.; Zanetti, N.; DiMeco, F.; et al. The EphA2
Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas. Cancer Cell
2012, 22, 765–780. [CrossRef]
Brain Sci. 2021, 11, 745 10 of 10
48. Perez-Costas, E.; Fenton, E.Y.; Caruncho, H.J. Reelin expression in brain endothelial cells: An electron microscopy study. BMC
Neurosci. 2015, 16, 1–8. [CrossRef]
49. Schulze, M.; Violonchi, C.; Swoboda, S.; Welz, T.; Kerkhoff, E.; Hoja, S.; Brüggemann, S.; Simbürger, J.; Reinders, J.; Riemenschnei-
der, M.J. RELN signaling modulates glioblastoma growth and substrate-dependent migration. Brain Pathol. 2018, 28, 695–709.
[CrossRef]
50. Geuna, S.; Herrera-Rincon, C. Update on stereology for light microscopy. Cell Tissue Res. 2015, 360, 5–12. [CrossRef]
51. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta
C(T)) Method. Methods 2001, 25, 402–408. [CrossRef] [PubMed]
52. Kim, H.M.; Qu, T.; Kriho, V.; Lacor, P.; Smalheiser, N.; Pappas, G.D.; Guidotti, A.; Costa, E.; Sugaya, K. Reelin function in neural
stem cell biology. Proc. Natl. Acad. Sci. USA 2002, 99, 4020–4025. [CrossRef] [PubMed]
53. Panteri, R.; Mey, J.; Zhelyaznik, N.; D’Altocolle, A.; Del Fà, A.; Gangitano, C.; Marino, R.; Lorenzetto, E.; Buffelli, M.; Keller, F.
Reelin is transiently expressed in the peripheral nerve during development and is upregulated following nerve crush. Mol. Cell.
Neurosci. 2006, 32, 133–142. [CrossRef] [PubMed]
54. Lutter, S.; Xie, S.; Tatin, F.; Makinen, T. Smooth muscle–endothelial cell communication activates Reelin signaling and regulates
lymphatic vessel formation. J. Cell Biol. 2012, 197, 837–849. [CrossRef]
55. Balzamino, B.O.; Esposito, G.; Marino, R.; Keller, F.; Micera, A. NGF Expression in Reelin-Deprived Retinal Cells: A Potential
Neuroprotective Effect. Neuromol. Med. 2015, 17, 314–325. [CrossRef]
56. Ding, Y.; Huang, L.; Xian, X.; Yuhanna, I.S.; Wasser, C.R.; Frotscher, M.; Mineo, C.; Shaul, P.W.; Herz, J. Loss of Reelin protects
against atherosclerosis by reducing leukocyte–endothelial cell adhesion and lesion macrophage accumulation. Sci. Signal. 2016,
9, ra29. [CrossRef]
57. Ohkubo, N.; Vitek, M.P.; Morishima, A.; Suzuki, Y.; Miki, T.; Maeda, N.; Mitsuda, N. Reelin signals survival through Src-family
kinases that inactivate BAD activity. J. Neurochem. 2007, 103, 820–830. [CrossRef]
